Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 5/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353271 | 0.90 | LMNA (0.34) | CYP2D6ALDH1A1LMNAKDM4EELANE | |
| SCHEMBL14517732 | 0.88 | FAAH (0.33) | CYP2D6OPRD1OPRK1 | |
| SCHEMBL5352932 | 0.87 | MAPK1 (0.34) | ALDH1A1LMNAKDM4EELANEESR1 | |
| SCHEMBL5338330 | 0.87 | LMNA (0.41) | CYP2D6OPRD1OPRK1ALDH1A1LMNA | |
| SCHEMBL6541980 | 0.87 | LMNA (0.41) | CYP2D6OPRD1OPRK1ALDH1A1LMNA | |
| SCHEMBL6541975 | 0.87 | LMNA (0.41) | CYP2D6OPRD1OPRK1ALDH1A1LMNA | |
| SCHEMBL5338872 | 0.84 | KDM4E (0.36) | LMNAKDM4EESR1CHRM1SLC6A4 | |
| SCHEMBL5345311 | 0.83 | TSHR (0.42) | — | |
| SCHEMBL5340133 | 0.83 | ADAMTS4 (0.35) | ALDH1A1LMNAKDM4ESMN1; SMN2ESR1 | |
| SCHEMBL5400428 | 0.82 | FOLH1 (0.33) | ELANECHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205291-B2 | High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20050020566-A1 | Novel carbapenem compounds | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1443047-A1 | NOVEL CARBAPENEM COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020566-A1 | Novel carbapenem compounds | HPN, PRSS1, BPGM | CYP2D6 3320/4885OPRD1 1531/4885OPRK1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.